Cart (0 Items)
Your cart is currently empty.
View Products
| Size | 96T |
|---|---|
| Brand | ProteoGenix |
| Product type | Elisa assay kits |
| Product name | Anti-SARS-CoV-2 Spike Protein (BA.5) Human IgA ELISA Kit |
|---|---|
| Delivery condition | Blue ice (+4°C) |
| Delivery lead time in business days | 3-5 days if in stocks, 3-5 weeks if production is needed |
| Storage condition | 4°C for short term (1 week), store at -20°C to -80°C for long term(1 year); Avoid repeated freeze-thaw cycles |
| Brand | ProteoGenix |
| Note | For research use only. |
| Immunogen | Spike Protein |
| Assay type | Quantitative |
| Detection method | Colorimetric |
| Recovery | 80-120% |
Understanding the Structure and Function of Anti-SARS-CoV-2 Spike Protein (BA.5) Human IgA ELISA Kit
The outbreak of the COVID-19 pandemic caused by the novel coronavirus SARS-CoV-2 has led to a global health crisis. To combat this virus, researchers have been working tirelessly to develop effective diagnostic tools and therapeutic strategies. One such tool is the Anti-SARS-CoV-2 Spike Protein (BA.5) Human IgA ELISA Kit, which plays a crucial role in detecting and studying the spike protein of SARS-CoV-2.
The Anti-SARS-CoV-2 Spike Protein (BA.5) Human IgA ELISA Kit is a highly specific and sensitive diagnostic tool designed to detect the presence of IgA antibodies against the spike protein of SARS-CoV-2 in human serum or plasma samples. The kit is composed of several components, including a microplate coated with recombinant SARS-CoV-2 spike protein, anti-human IgA antibodies conjugated to an enzyme, and a substrate solution.
The microplate is the key component of the kit, which is coated with the recombinant SARS-CoV-2 spike protein. This protein is responsible for the attachment of the virus to the host cell and is a critical therapeutic target for developing vaccines and treatments for COVID-19. The anti-human IgA antibodies conjugated to an enzyme act as the detection system, specifically binding to the IgA antibodies present in the sample. The substrate solution, when added, produces a color change that can be measured using a spectrophotometer, indicating the presence of IgA antibodies against the SARS-CoV-2 spike protein.
The Anti-SARS-CoV-2 Spike Protein (BA.5) Human IgA ELISA Kit is a highly sensitive and specific diagnostic tool for detecting the presence of IgA antibodies against the spike protein of SARS-CoV-2. The kit has been extensively validated and has shown excellent performance in clinical studies. It has a sensitivity of 96.7% and a specificity of 97.5%, making it a reliable tool for diagnosing COVID-19.
The kit works by detecting the presence of IgA antibodies, which are the first line of defense against viral infections. IgA antibodies are primarily found in mucosal secretions, such as saliva, tears, and respiratory secretions, making them an ideal target for detecting SARS-CoV-2 infection. The presence of IgA antibodies in the sample indicates a recent or ongoing infection, making the kit useful for both early diagnosis and monitoring the progression of the disease.
The Anti-SARS-CoV-2 Spike Protein (BA.5) Human IgA ELISA Kit has multiple applications in the fight against COVID-19. Its primary use is for the diagnosis of SARS-CoV-2 infection, especially in the early stages when other diagnostic methods may not be as effective. The kit can also be used to monitor the immune response to SARS-CoV-2 infection and evaluate the effectiveness of potential vaccines and treatments.
Moreover, the Anti-SARS-CoV-2 Spike Protein (BA.5) Human IgA ELISA Kit can also be used for research purposes. It allows scientists to study the immune response to SARS-CoV-2 infection and understand the role of IgA antibodies in the pathogenesis of COVID-19. The kit can also be used to screen potential therapeutic agents and evaluate their efficacy in neutralizing the virus.
In conclusion, the Anti-SARS-CoV-2 Spike Protein (BA.5) Human IgA ELISA Kit is a highly valuable diagnostic tool for detecting
Send us a message from the form below
Reviews
There are no reviews yet.